- Home
- MBOT vs UNCY Comparison
MBOT vs UNCY Comparison
Compare MBOT & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBOT | UNCY |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.6M | 145.3M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MBOT | UNCY |
|---|---|---|
| Price | $2.34 | $7.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $7.50 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 1.4M | 526.8K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $116,887.00 | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.77 | $407.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.47 |
| 52 Week High | $4.62 | $7.57 |
Technical Indicators
Market Signals| Indicator | MBOT | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 55.74 |
| Support Level | $1.99 | $5.95 |
| Resistance Level | $2.67 | $7.12 |
| Average True Range (ATR) | 0.15 | 0.40 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 22.28 | 68.46 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.